BR9809242A - Nucleotìdeos anti-sentido modificados complementares a uma seção do gene ha-ras humano - Google Patents

Nucleotìdeos anti-sentido modificados complementares a uma seção do gene ha-ras humano

Info

Publication number
BR9809242A
BR9809242A BR9809242-1A BR9809242A BR9809242A BR 9809242 A BR9809242 A BR 9809242A BR 9809242 A BR9809242 A BR 9809242A BR 9809242 A BR9809242 A BR 9809242A
Authority
BR
Brazil
Prior art keywords
ras gene
human
section
integer
modified
Prior art date
Application number
BR9809242-1A
Other languages
English (en)
Inventor
Eugen Uhlmann
Anuschirwan Peyman
David William Will
Esther Chang
Kathleen Pirollo
Antonina Rait
Original Assignee
Hoechst Marion Russel Deutschl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Marion Russel Deutschl filed Critical Hoechst Marion Russel Deutschl
Publication of BR9809242A publication Critical patent/BR9809242A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3531—Hydrogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Patente de Invenção:<B>NUCLEOTìDEOS ANTI-SENTIDO MODIFICADOS COMPLEMENTARES A UMA SEçãO DO GENE HA-RAS HUMANO"<D>. A invenção refere-se a um oligodeoxicleotídeo modificado específico complementar a uma seção do gene Ha-ras humano e mRNA e a seu uso para regular, modular ou inibir especificamente, a expressão do gene Ha-ras e a seu uso como um produto farmacêutico para o tratamento de condições que surgem da expressão anormal do gene Ha-ras, em particular, em combinação com quimioterapia e radioterapia. O oligodeoxicleotídeo modificado de acordo com a invenção possui a seq³ência: 5'-TxAxTxTxCxCxGxTxCxAxT-3'O-Po~ 2~-O-R, em que X é 0 ou s, com a condição de que x seja 4 a 9 vezes igual a s e o significa uma ligação internucleosídeo fosfodiéster, s significa uma ligação, internucleosídeo fosforotioato, R significa um grupo C~8-21~ alquila, -(CH~ 2~CH~ 2~O)~ n~-(CH~ 2~)~ m~-CH~ 3~ ou CH~ 2~-CH(OH)CH~ 2~O-(CH~ 2~)~ q~-CH~ 3~, em que n é um número inteiro de 1 a 6, m é um número inteiro de 0 a 20 e q é um n° inteiro de 7 a 20 e A é 2'-desoxiadenosina, G é 2'-desoxiguanosina, C é 2'-desocicitidina e T é timidina.
BR9809242-1A 1997-05-05 1998-04-30 Nucleotìdeos anti-sentido modificados complementares a uma seção do gene ha-ras humano BR9809242A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97107404 1997-05-05
PCT/EP1998/002546 WO1998050540A1 (en) 1997-05-05 1998-04-30 MODIFIED ANTISENSE NUCLEOTIDES COMPLEMENTARY TO A SECTION OF THE HUMAN Ha-Ras GENE

Publications (1)

Publication Number Publication Date
BR9809242A true BR9809242A (pt) 2000-06-27

Family

ID=8226765

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9809242-1A BR9809242A (pt) 1997-05-05 1998-04-30 Nucleotìdeos anti-sentido modificados complementares a uma seção do gene ha-ras humano

Country Status (10)

Country Link
US (2) US6723706B2 (pt)
EP (1) EP0979273A1 (pt)
JP (1) JP2002501505A (pt)
KR (1) KR100518108B1 (pt)
CN (1) CN1304572C (pt)
AU (1) AU744417B2 (pt)
BR (1) BR9809242A (pt)
CA (1) CA2288946A1 (pt)
HU (1) HUP0100044A3 (pt)
WO (1) WO1998050540A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6368855B1 (en) * 1996-06-11 2002-04-09 Antigen Express, Inc. MHC class II antigen presenting cells containing oligonucleotides which inhibit Ii protein expression
US8202979B2 (en) * 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
US20090099117A1 (en) * 2002-02-20 2009-04-16 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF MYOSTATIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US7713738B2 (en) 2003-02-10 2010-05-11 Enzon Pharmaceuticals, Inc. Oligomeric compounds for the modulation of survivin expression
WO2005099363A2 (en) 2004-03-26 2005-10-27 Whitehead Institute For Biomedical Research Methods of diagnosing, preventing and treating cancer metastasis
WO2006050732A2 (en) 2004-11-09 2006-05-18 Santaris Pharma A/S Lna oligonucleotides and the treatment of cancer
CN101522717A (zh) 2006-08-04 2009-09-02 阿斯利康(瑞典)有限公司 针对ErbB2的人抗体
US8569252B2 (en) * 2009-04-15 2013-10-29 Postech Academy-Industry Foundation Nucleolin specific aptamer and use thereof
CN104884618A (zh) 2012-11-15 2015-09-02 罗氏创新中心哥本哈根有限公司 寡核苷酸缀合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5245022A (en) * 1990-08-03 1993-09-14 Sterling Drug, Inc. Exonuclease resistant terminally substituted oligonucleotides
WO1994008003A1 (en) * 1991-06-14 1994-04-14 Isis Pharmaceuticals, Inc. ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE ras GENE
CA2111472A1 (en) 1991-06-14 1992-12-23 Brett P. Monia Antisense oligonucleotide inhibition of the ras gene
US5582986A (en) 1991-06-14 1996-12-10 Isis Pharmaceuticals, Inc. Antisense oligonucleotide inhibition of the ras gene
NZ245720A (en) * 1992-01-22 1995-12-21 Hoechst Ag Oligonucleotide analogues; use as gene expression inhibitor or dna probe
WO1994008625A1 (en) * 1992-10-21 1994-04-28 Temple University - Of The Commonwealth System Of Higher Education Combination of antineoplastic agent and antisense oligonucleotides for treatment of cancer
DE4338704A1 (de) * 1993-11-12 1995-05-18 Hoechst Ag Stabilisierte Oligonucleotide und deren Verwendung
US5696248A (en) * 1994-06-15 1997-12-09 Hoechst Aktiengesellschaft 3'-modified oligonucleotide derivatives

Also Published As

Publication number Publication date
KR20010012238A (ko) 2001-02-15
CN1255164A (zh) 2000-05-31
JP2002501505A (ja) 2002-01-15
HUP0100044A3 (en) 2003-08-28
WO1998050540A1 (en) 1998-11-12
KR100518108B1 (ko) 2005-10-04
EP0979273A1 (en) 2000-02-16
US20050020523A1 (en) 2005-01-27
CN1304572C (zh) 2007-03-14
CA2288946A1 (en) 1998-11-12
HUP0100044A1 (hu) 2001-05-28
AU7760298A (en) 1998-11-27
US20030064514A1 (en) 2003-04-03
US6723706B2 (en) 2004-04-20
AU744417B2 (en) 2002-02-21

Similar Documents

Publication Publication Date Title
ES2817050T3 (es) Compuestos antisentido selectivos y usos de los mismos
AU2013280474B2 (en) Modulation of UBE3A-ATS expression
DK0928335T3 (da) Fremgangsmåde til anvendelse af oligonukleotider med modificerede CpG-dinukleosider
Dennis et al. Human melanoma metastasis is inhibited following ex vivo treatment with an antisense oligonucleotide to protein kinase C-α
DK0677056T3 (da) Oligonukleotid-alkylphosphonater og -alkylphosphonothioater
EA029137B1 (ru) Модулирование экспрессии вируса гепатита в (hbv)
PT731835E (pt) Oligonucleotidos anti-sentido possuindo actividade inibidora de tumorigenicidade
JP2016523087A (ja) 標的核酸を調節するための組成物および方法
BR9809242A (pt) Nucleotìdeos anti-sentido modificados complementares a uma seção do gene ha-ras humano
PT1390039E (pt) Utilizacao de compostos estrogenicos para aumentar a libido nas mulheres
MX2015004641A (es) Modulacion de la expresion del receptor androgenico.
JP7289347B2 (ja) Ｐｃｓｋ９発現のモジュレーター
CA3103429A1 (en) Compounds and methods for increasing stmn2 expression
JP7239597B2 (ja) Ｉｒｆ４発現の調節因子
JP2016523548A (ja) 成長ホルモン受容体のモジュレータ
US20110172296A1 (en) Modulation of transforming growth factor-beta 1 expression
US20170362592A1 (en) Modulation of ube3a-ats expression
IL121272A0 (en) Nucleotide comprising compositions and their use for improving therapeutic index of a therapeutic drug
CA3088522A1 (en) Modulators of dnm2 expression
Pisetsky Mechanisms of immune stimulation by bacterial DNA
US20150284725A1 (en) Methods of treating kennedy&#39;s disease
KR20090035662A (ko) 포스포디에스테라아제의 발현에 영향을 미치는 올리고누클레오티드
WO2019099781A1 (en) Methods of modulating antisense activity
WO2015051239A1 (en) Methods for increasing neuronal survival
WO2013130868A1 (en) Methods for modulating fibrinogen expression

Legal Events

Date Code Title Description
TC Change of name
B25D Requested change of name of applicant approved

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH (DE)

Free format text: ALTERADO DE: AVENTIS PHARMA DEUTSCHLAND GMBH

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: O DEPOSITANTE DEIXOU DE APRESENTAR MANIFESTACAO SOBRE O PARECER NEGATIVO, ASSIM, DE ACORDO COM O ART. 36 DA LPI (LEI 9279/96) 2O, O PEDIDO VOLTA A EXAME SENDO CONSIDERADO NAO PATENTEAVEL PELAS RAZOES EXPOSTAS NO PARECER TECNICO ANTERIOR.